Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function

被引:540
|
作者
Basso, AD
Solit, DB
Chiosis, G
Giri, B
Tsichlis, P
Rosen, N
机构
[1] Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[3] Thomas Jefferson Univ, Kimmel Canc, Philadelphia, PA 19107 USA
[4] Cornell Univ, Weill Grad Sch Med Sci, Program Pharmacol, Philadelphia, PA 19107 USA
关键词
D O I
10.1074/jbc.M206322200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hsp90 is a chaperone required for the conformational maturation of certain signaling proteins including Raf, cdk4, and steroid receptors. Natural products and synthetic small molecules that bind to the ATP-binding pocket in the amino-terminal domain of Hsp90 inhibit its function and cause the degradation of these client proteins. Inhibition of Hsp90 function in cells causes down-regulation of an Akt kinase-dependent pathway required for D-cyclin expression and retinoblastoma protein-dependent G, arrest. Intracellular Akt is associated with Hsp90 and Cdc37 in a complex in which Akt kinase is active and regulated by phosphatidylinositol 3-kinase. Functional Hsp90 is required for the stability of Akt in the complex. Occupancy of the ATP-binding pocket by inhibitors is associated with the ubiquitination of Akt and its targeting to the proteasome, where it is degraded. This results in a shortening of the half-life of Akt from 36 to 12 h and an 80% reduction in its expression. Akt and its activating kinase, PDK1, are the only members of the protein kinase A/protein kinase B/protein kinase C-like kinase family that are affected by Hsp90 inhibitors. Thus, transduction of growth factor signaling via the Akt and Raf pathways requires functional Hsp90 and can be coordinately blocked by its inhibition.
引用
收藏
页码:39858 / 39866
页数:9
相关论文
共 50 条
  • [1] Silencing of the heat shock protein 90 (HSP90) cochaperone CDC37 by RNA interference sensitises cancer cells to HSP90 inhibitors
    Smith, Jennifer
    Clarke, Paul
    Workman, Paul
    CANCER RESEARCH, 2008, 68 (09)
  • [2] A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
    Zhang, Tao
    Hamza, Adel
    Cao, Xianhua
    Wang, Bing
    Yu, Shuwen
    Zhan, Chang-Guo
    Sun, Duxin
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (01) : 162 - 170
  • [3] Interaction of cepharanthine with immobilized heat shock protein 90α (Hsp90α) and screening of Hsp90α inhibitors
    Haginaka, Jun
    Kitabatake, Tomoko
    Hirose, Iyo
    Matsunaga, Hisami
    Moaddel, Ruin
    ANALYTICAL BIOCHEMISTRY, 2013, 434 (01) : 202 - 206
  • [4] Hsp90 and Cdc37 - a chaperone cancer conspiracy
    Pearl, LH
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 2005, 15 (01) : 55 - 61
  • [5] Cdc37 goes beyond Hsp90 and kinases
    MacLean, M
    Picard, D
    CELL STRESS & CHAPERONES, 2003, 8 (02): : 114 - 119
  • [6] Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors
    Wang, Yao
    Koay, Yen Chin
    McAlpine, Shelli R.
    CHEMISTRY-A EUROPEAN JOURNAL, 2017, 23 (09) : 2010 - 2013
  • [7] Heat Shock Protein 90 (Hsp90) Preface
    Picard, Didier
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2012, 1823 (03): : 605 - 606
  • [8] Biochemical and structural studies of the interaction of Cdc37 with Hsp90
    Zhang, W
    Hirshberg, M
    McLaughlin, SH
    Lazar, GA
    Grossmann, JG
    Nielsen, PR
    Sobott, F
    Robinson, CV
    Jackson, SE
    Laue, ED
    JOURNAL OF MOLECULAR BIOLOGY, 2004, 340 (04) : 891 - 907
  • [9] Characterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction
    Zhang, Tao
    Li, Yanyan
    Yu, Yanke
    Zou, Peng
    Jiang, Yiqun
    Sun, Duxin
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (51) : 35381 - 35389
  • [10] Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor
    Li, Ting
    Chen, Xin
    Dai, Xiao-Yang
    Wei, Bin
    Weng, Qin-Jie
    Chen, Xiuping
    Ouyang, De-Fang
    Yan, Ru
    Huang, Zhang-Jian
    Jiang, Hu-Lin
    Zhu, Hong
    Lu, Jin-Jian
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2017, 330 : 65 - 73